US11259554B2 - Dietary peptides - Google Patents
Dietary peptides Download PDFInfo
- Publication number
- US11259554B2 US11259554B2 US16/062,429 US201616062429A US11259554B2 US 11259554 B2 US11259554 B2 US 11259554B2 US 201616062429 A US201616062429 A US 201616062429A US 11259554 B2 US11259554 B2 US 11259554B2
- Authority
- US
- United States
- Prior art keywords
- seq
- amino acid
- polypeptide
- acid selected
- dosage form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 233
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 184
- 235000005911 diet Nutrition 0.000 title description 5
- 230000000378 dietary effect Effects 0.000 title description 4
- 239000000203 mixture Substances 0.000 claims abstract description 64
- 229920001184 polypeptide Polymers 0.000 claims description 126
- 150000001413 amino acids Chemical class 0.000 claims description 93
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 35
- 229910052740 iodine Inorganic materials 0.000 claims description 24
- 239000006186 oral dosage form Substances 0.000 claims description 20
- 229910052757 nitrogen Inorganic materials 0.000 claims description 16
- 229910052717 sulfur Inorganic materials 0.000 claims description 14
- 229910052698 phosphorus Inorganic materials 0.000 claims description 11
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 230000037406 food intake Effects 0.000 claims description 4
- 235000012631 food intake Nutrition 0.000 claims description 3
- 238000000034 method Methods 0.000 abstract description 26
- 230000036186 satiety Effects 0.000 abstract description 25
- 235000019627 satiety Nutrition 0.000 abstract description 25
- 208000008589 Obesity Diseases 0.000 abstract description 14
- 235000020824 obesity Nutrition 0.000 abstract description 14
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 11
- 206010020772 Hypertension Diseases 0.000 abstract description 11
- 206010028980 Neoplasm Diseases 0.000 abstract description 11
- 201000011510 cancer Diseases 0.000 abstract description 11
- 201000001320 Atherosclerosis Diseases 0.000 abstract description 9
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 9
- 235000019553 satiation Nutrition 0.000 abstract description 9
- 230000001939 inductive effect Effects 0.000 abstract description 5
- 235000015872 dietary supplement Nutrition 0.000 abstract description 4
- 230000037221 weight management Effects 0.000 abstract description 4
- 235000001014 amino acid Nutrition 0.000 description 82
- 229940024606 amino acid Drugs 0.000 description 76
- 230000000694 effects Effects 0.000 description 37
- 210000004027 cell Anatomy 0.000 description 28
- 235000013305 food Nutrition 0.000 description 22
- 210000000936 intestine Anatomy 0.000 description 19
- 230000000968 intestinal effect Effects 0.000 description 17
- 230000015556 catabolic process Effects 0.000 description 16
- 238000006731 degradation reaction Methods 0.000 description 16
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 15
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 238000006467 substitution reaction Methods 0.000 description 15
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 description 14
- 238000003556 assay Methods 0.000 description 13
- PCJGZPGTCUMMOT-ISULXFBGSA-N neurotensin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 PCJGZPGTCUMMOT-ISULXFBGSA-N 0.000 description 13
- 235000018102 proteins Nutrition 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 12
- 125000000539 amino acid group Chemical group 0.000 description 12
- TZCYVPLNMOJUIL-UHFFFAOYSA-N 2-[[2-[[2-[[1-[6-amino-2-(2,6-diaminohexylamino)hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-4-methylpentanoic acid Chemical compound C1CCN(C(=O)C(CCCCN)NCC(N)CCCCN)C1C(=O)NC(C(=O)NC(C(C)CC)C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 TZCYVPLNMOJUIL-UHFFFAOYSA-N 0.000 description 11
- 101800001814 Neurotensin Proteins 0.000 description 10
- 102400001103 Neurotensin Human genes 0.000 description 10
- 235000013351 cheese Nutrition 0.000 description 10
- 210000001035 gastrointestinal tract Anatomy 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 229910052721 tungsten Inorganic materials 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 239000012091 fetal bovine serum Substances 0.000 description 9
- 238000011534 incubation Methods 0.000 description 9
- 241000894007 species Species 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 229910052727 yttrium Inorganic materials 0.000 description 9
- 239000012981 Hank's balanced salt solution Substances 0.000 description 8
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 7
- 102100032964 Alpha-actinin-2 Human genes 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 7
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 7
- 239000007995 HEPES buffer Substances 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
- 238000011049 filling Methods 0.000 description 7
- 235000012041 food component Nutrition 0.000 description 7
- 239000005417 food ingredient Substances 0.000 description 7
- 235000013376 functional food Nutrition 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- 239000003531 protein hydrolysate Substances 0.000 description 7
- 230000002797 proteolythic effect Effects 0.000 description 7
- 230000011664 signaling Effects 0.000 description 7
- 230000009897 systematic effect Effects 0.000 description 7
- 101710115259 Alpha-actinin-2 Proteins 0.000 description 6
- UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 description 6
- 229910052731 fluorine Inorganic materials 0.000 description 6
- 239000003629 gastrointestinal hormone Substances 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 235000016709 nutrition Nutrition 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 235000015067 sauces Nutrition 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 241001529936 Murinae Species 0.000 description 5
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- 229910052791 calcium Inorganic materials 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- -1 cyclic amino acids Chemical class 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 235000021050 feed intake Nutrition 0.000 description 5
- 238000011065 in-situ storage Methods 0.000 description 5
- 235000013372 meat Nutrition 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 210000000813 small intestine Anatomy 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 4
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 206010033307 Overweight Diseases 0.000 description 4
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 4
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 230000000975 bioactive effect Effects 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 235000012970 cakes Nutrition 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 210000003158 enteroendocrine cell Anatomy 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000005714 functional activity Effects 0.000 description 4
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 4
- 235000015243 ice cream Nutrition 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000009117 preventive therapy Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- 208000001145 Metabolic Syndrome Diseases 0.000 description 3
- 229930193140 Neomycin Natural products 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 102000057297 Pepsin A Human genes 0.000 description 3
- 108090000284 Pepsin A Proteins 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 102100029909 Peptide YY Human genes 0.000 description 3
- 108010088847 Peptide YY Proteins 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 108010009736 Protein Hydrolysates Proteins 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 244000299461 Theobroma cacao Species 0.000 description 3
- JAQGKXUEKGKTKX-HOTGVXAUSA-N Tyr-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 JAQGKXUEKGKTKX-HOTGVXAUSA-N 0.000 description 3
- 108010046377 Whey Proteins Proteins 0.000 description 3
- 102000007544 Whey Proteins Human genes 0.000 description 3
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- QOMNQGZXFYNBNG-UHFFFAOYSA-N acetyloxymethyl 2-[2-[2-[5-[3-(acetyloxymethoxy)-2,7-difluoro-6-oxoxanthen-9-yl]-2-[bis[2-(acetyloxymethoxy)-2-oxoethyl]amino]phenoxy]ethoxy]-n-[2-(acetyloxymethoxy)-2-oxoethyl]-4-methylanilino]acetate Chemical compound CC(=O)OCOC(=O)CN(CC(=O)OCOC(C)=O)C1=CC=C(C)C=C1OCCOC1=CC(C2=C3C=C(F)C(=O)C=C3OC3=CC(OCOC(C)=O)=C(F)C=C32)=CC=C1N(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O QOMNQGZXFYNBNG-UHFFFAOYSA-N 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- 230000005754 cellular signaling Effects 0.000 description 3
- 238000007385 chemical modification Methods 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 235000013365 dairy product Nutrition 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 235000004213 low-fat Nutrition 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 208000030159 metabolic disease Diseases 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 229960004927 neomycin Drugs 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 239000002417 nutraceutical Substances 0.000 description 3
- 235000021436 nutraceutical agent Nutrition 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 229940111202 pepsin Drugs 0.000 description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 108010003137 tyrosyltyrosine Proteins 0.000 description 3
- 235000021119 whey protein Nutrition 0.000 description 3
- 235000013618 yogurt Nutrition 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- DQDBCHHEIKQPJD-ODKJCKIQSA-N (2s)-2-[[(2s,3s)-2-[[(2s)-2-[[(2s)-1-[(2s)-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-4-methylpentanoic acid Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CCCN=C(N)N)C1=CC=C(O)C=C1 DQDBCHHEIKQPJD-ODKJCKIQSA-N 0.000 description 2
- TZCYVPLNMOJUIL-GULBXNHPSA-N (2s)-2-[[(2s,3s)-2-[[(2s)-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-2,6-diaminohexyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-4-methylpentanoic acid Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC[C@@H](N)CCCCN)C1=CC=C(O)C=C1 TZCYVPLNMOJUIL-GULBXNHPSA-N 0.000 description 2
- PDRJLZDUOULRHE-ZETCQYMHSA-N (2s)-2-amino-3-pyridin-2-ylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=N1 PDRJLZDUOULRHE-ZETCQYMHSA-N 0.000 description 2
- DFZVZEMNPGABKO-ZETCQYMHSA-N (2s)-2-amino-3-pyridin-3-ylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=CN=C1 DFZVZEMNPGABKO-ZETCQYMHSA-N 0.000 description 2
- FQFVANSXYKWQOT-ZETCQYMHSA-N (2s)-2-azaniumyl-3-pyridin-4-ylpropanoate Chemical compound OC(=O)[C@@H](N)CC1=CC=NC=C1 FQFVANSXYKWQOT-ZETCQYMHSA-N 0.000 description 2
- XWHHYOYVRVGJJY-QMMMGPOBSA-N 4-fluoro-L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(F)C=C1 XWHHYOYVRVGJJY-QMMMGPOBSA-N 0.000 description 2
- 102100032956 Alpha-actinin-3 Human genes 0.000 description 2
- 102100032959 Alpha-actinin-4 Human genes 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 208000032928 Dyslipidaemia Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 239000001828 Gelatine Substances 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 description 2
- 108010070551 Meat Proteins Proteins 0.000 description 2
- 108020004485 Nonsense Codon Proteins 0.000 description 2
- 108091060545 Nonsense suppressor Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 102400000752 Xenin Human genes 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 230000003305 autocrine Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 235000015895 biscuits Nutrition 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- PMMYEEVYMWASQN-IMJSIDKUSA-N cis-4-Hydroxy-L-proline Chemical compound O[C@@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-IMJSIDKUSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000014510 cooky Nutrition 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 235000011850 desserts Nutrition 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000000413 hydrolysate Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 238000001155 isoelectric focusing Methods 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 230000037434 nonsense mutation Effects 0.000 description 2
- 230000003076 paracrine Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- IDHVLSACPFUBDY-QCDLPZBNSA-N xenin Chemical compound C([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CN=CN1 IDHVLSACPFUBDY-QCDLPZBNSA-N 0.000 description 2
- 108010006643 xenin 25 Proteins 0.000 description 2
- UJXJZOCXEZPHIE-YFKPBYRVSA-N (2s)-2-(2-hydroxyethylamino)-4-sulfanylbutanoic acid Chemical compound OCCN[C@H](C(O)=O)CCS UJXJZOCXEZPHIE-YFKPBYRVSA-N 0.000 description 1
- JQFLYFRHDIHZFZ-RXMQYKEDSA-N (2s)-3,3-dimethylpyrrolidine-2-carboxylic acid Chemical compound CC1(C)CCN[C@@H]1C(O)=O JQFLYFRHDIHZFZ-RXMQYKEDSA-N 0.000 description 1
- CNPSFBUUYIVHAP-AKGZTFGVSA-N (2s)-3-methylpyrrolidine-2-carboxylic acid Chemical compound CC1CCN[C@@H]1C(O)=O CNPSFBUUYIVHAP-AKGZTFGVSA-N 0.000 description 1
- FXGZFWDCXQRZKI-VKHMYHEASA-N (2s)-5-amino-2-nitramido-5-oxopentanoic acid Chemical compound NC(=O)CC[C@@H](C(O)=O)N[N+]([O-])=O FXGZFWDCXQRZKI-VKHMYHEASA-N 0.000 description 1
- CCAIIPMIAFGKSI-DMTCNVIQSA-N (2s,3r)-3-hydroxy-2-(methylazaniumyl)butanoate Chemical compound CN[C@@H]([C@@H](C)O)C(O)=O CCAIIPMIAFGKSI-DMTCNVIQSA-N 0.000 description 1
- CNPSFBUUYIVHAP-WHFBIAKZSA-N (2s,3s)-3-methylpyrrolidin-1-ium-2-carboxylate Chemical compound C[C@H]1CCN[C@@H]1C(O)=O CNPSFBUUYIVHAP-WHFBIAKZSA-N 0.000 description 1
- NGJOFQZEYQGZMB-KTKZVXAJSA-N (4S)-5-[[2-[[(2S,3R)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[2-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-2-oxoethyl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-2-oxoethyl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-4-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]propanoyl]amino]-5-oxopentanoic acid Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 NGJOFQZEYQGZMB-KTKZVXAJSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- OMGHIGVFLOPEHJ-UHFFFAOYSA-N 2,5-dihydro-1h-pyrrol-1-ium-2-carboxylate Chemical compound OC(=O)C1NCC=C1 OMGHIGVFLOPEHJ-UHFFFAOYSA-N 0.000 description 1
- XEVFXAFXZZYFSX-UHFFFAOYSA-N 3-azabicyclo[2.1.1]hexane-4-carboxylic acid Chemical compound C1C2CC1(C(=O)O)NC2 XEVFXAFXZZYFSX-UHFFFAOYSA-N 0.000 description 1
- 102100034163 Alpha-actinin-1 Human genes 0.000 description 1
- 101710115082 Alpha-actinin-1 Proteins 0.000 description 1
- 101710115089 Alpha-actinin-3 Proteins 0.000 description 1
- 101710115256 Alpha-actinin-4 Proteins 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 241000244203 Caenorhabditis elegans Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 241000252212 Danio rerio Species 0.000 description 1
- 241000168726 Dictyostelium discoideum Species 0.000 description 1
- 241000255601 Drosophila melanogaster Species 0.000 description 1
- 206010014486 Elevated triglycerides Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 101800004295 Glucagon-like peptide 1(7-36) Proteins 0.000 description 1
- 101800004266 Glucagon-like peptide 1(7-37) Proteins 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 101000799406 Homo sapiens Alpha-actinin-1 Proteins 0.000 description 1
- 101000797275 Homo sapiens Alpha-actinin-2 Proteins 0.000 description 1
- 101000797292 Homo sapiens Alpha-actinin-3 Proteins 0.000 description 1
- 101000797282 Homo sapiens Alpha-actinin-4 Proteins 0.000 description 1
- 101500028772 Homo sapiens Glucagon-like peptide 1(7-36) Proteins 0.000 description 1
- YZJSUQQZGCHHNQ-UHFFFAOYSA-N Homoglutamine Chemical compound OC(=O)C(N)CCCC(N)=O YZJSUQQZGCHHNQ-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
- HXEACLLIILLPRG-YFKPBYRVSA-N L-pipecolic acid Chemical compound [O-]C(=O)[C@@H]1CCCC[NH2+]1 HXEACLLIILLPRG-YFKPBYRVSA-N 0.000 description 1
- DZLNHFMRPBPULJ-VKHMYHEASA-N L-thioproline Chemical compound OC(=O)[C@@H]1CSCN1 DZLNHFMRPBPULJ-VKHMYHEASA-N 0.000 description 1
- KKJQZEWNZXRJFG-UHFFFAOYSA-N L-trans-4-Methyl-2-pyrrolidinecarboxylic acid Chemical compound CC1CNC(C(O)=O)C1 KKJQZEWNZXRJFG-UHFFFAOYSA-N 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- 108010074084 Muscle Proteins Proteins 0.000 description 1
- 102000008934 Muscle Proteins Human genes 0.000 description 1
- 101800001607 Neuromedin N Proteins 0.000 description 1
- 102400001104 Neuromedin N Human genes 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108010058003 Proglucagon Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 241000269370 Xenopus <genus> Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000000689 aminoacylating effect Effects 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000000923 atherogenic effect Effects 0.000 description 1
- 235000015173 baked goods and baking mixes Nutrition 0.000 description 1
- 235000021168 barbecue Nutrition 0.000 description 1
- 229940006612 barium citrate Drugs 0.000 description 1
- PAVWOHWZXOQYDB-UHFFFAOYSA-H barium(2+);2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Ba+2].[Ba+2].[Ba+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PAVWOHWZXOQYDB-UHFFFAOYSA-H 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- 150000001576 beta-amino acids Chemical class 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000015496 breakfast cereal Nutrition 0.000 description 1
- 210000003123 bronchiole Anatomy 0.000 description 1
- 235000012839 cake mixes Nutrition 0.000 description 1
- 230000003185 calcium uptake Effects 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 210000004671 cell-free system Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000004098 cellular respiration Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 235000020140 chocolate milk drink Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000011098 chromatofocusing Methods 0.000 description 1
- 235000013353 coffee beverage Nutrition 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 235000015142 cultured sour cream Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 239000000385 dialysis solution Substances 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- ZCKYOWGFRHAZIQ-UHFFFAOYSA-N dihydrourocanic acid Chemical compound OC(=O)CCC1=CNC=N1 ZCKYOWGFRHAZIQ-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- ZWIBGKZDAWNIFC-UHFFFAOYSA-N disuccinimidyl suberate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCCC(=O)ON1C(=O)CCC1=O ZWIBGKZDAWNIFC-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 235000012489 doughnuts Nutrition 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 210000001842 enterocyte Anatomy 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013332 fish product Nutrition 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 208000020694 gallbladder disease Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- MWFRVMDVLYIXJF-BYPYZUCNSA-N hydroxyethylcysteine Chemical compound OC(=O)[C@@H](N)CSCCO MWFRVMDVLYIXJF-BYPYZUCNSA-N 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 235000008446 instant noodles Nutrition 0.000 description 1
- 235000014109 instant soup Nutrition 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000010829 isocratic elution Methods 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- HXEACLLIILLPRG-RXMQYKEDSA-N l-pipecolic acid Natural products OC(=O)[C@H]1CCCCN1 HXEACLLIILLPRG-RXMQYKEDSA-N 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- RZMLVIHXZGQADB-YLUGYNJDSA-N neuromedin n Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)[C@@H](C)CC)C1=CC=C(O)C=C1 RZMLVIHXZGQADB-YLUGYNJDSA-N 0.000 description 1
- 108010081387 neurotensin (8-13) Proteins 0.000 description 1
- 108010077353 neurotensin (9-13) Proteins 0.000 description 1
- 102000020232 neurotensin type 1 receptor Human genes 0.000 description 1
- 108010016501 neurotensin type 1 receptor Proteins 0.000 description 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 235000014594 pastries Nutrition 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000002186 photoactivation Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920001992 poloxamer 407 Polymers 0.000 description 1
- 235000013613 poultry product Nutrition 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000009561 snack bars Nutrition 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 229960001471 sodium selenite Drugs 0.000 description 1
- 239000011781 sodium selenite Substances 0.000 description 1
- 235000015921 sodium selenite Nutrition 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000003019 stabilising effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- NPDBDJFLKKQMCM-UHFFFAOYSA-N tert-butylglycine Chemical compound CC(C)(C)C(N)C(O)=O NPDBDJFLKKQMCM-UHFFFAOYSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 229940035722 triiodothyronine Drugs 0.000 description 1
- 238000009966 trimming Methods 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 239000006213 vaginal ring Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 235000008924 yoghurt drink Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/03—Organic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4716—Muscle proteins, e.g. myosin, actin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57509—Corticotropin releasing factor [CRF] (Urotensin)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to novel peptides, composition comprising such peptides including nutritional supplements and methods for inducing satiation and satiety, for preventing or reducing the incidence of metabolic syndrome comprising overweight and obesity, cardiovascular diseases, atherosclerosis, hypertension, hepatosteatosis, diabetes and/or cancer.
- sequence listing is submitted concurrently with the specification as a text file via EFS-Web, in compliance with the American Standard Code for Information Interchange (ASCII), with a file name of 20549US00_July_2021_ST25.txt, a creation date of Jul. 23, 2021, and a size of 191 Kb.
- ASCII American Standard Code for Information Interchange
- the sequence listing filed via EFS-Web is part of the specification and is hereby incorporated in its entirety by reference herein.
- Obesity is a common medical condition affecting numerous humans throughout the world and is associated with, induces or increases the risk of developing conditions such as cardiovascular diseases, atherosclerosis, hypertension, hepatosteatosis, cancer and/or diabetes.
- Protein is more satiating than carbohydrate and fat, and its effect on food intake is more than can be accounted for by its energy content alone.
- the mechanism by which proteins trigger food intake regulatory systems is unclear. However, it seems likely that satiety signals arising from protein ingestion begin in the gastrointestinal tract upon proteolytic digestion.
- dietary proteolytic products induce signalling in enteroendocrine cells of the intestine, which leads to secretion of various gut hormones, e.g. glucagon-like peptide-1 (GLP-1) ( FIG. 1 ) with neuronal, local (auto- and paracrine) and systemic (endocrine) effects ( FIG. 2 ), ultimately leading to satiation (amount of food ingested as a meal) and satiety (length of time between meals).
- GLP-1 glucagon-like peptide-1
- FIG. 2 glucagon-like peptide-1
- enteroendocrine cells respond to free amino acids and small peptides (di- and tripeptides), which are readily taken up by the enterocytes and metabolized and/or transported into systemic circulation.
- Rate of digestion i.e. transit time in the GI tract, secretion of digestive enzymes, etc, is a highly regulated process, where cellular responses to undigested proteins and/or increases in amino acids and peptides in the gut leads to secretion of gut hormones, e.g. GLP-1, peptide tyrosine-tyrosine (PYY), neurotensin (NT), which induces satiation. If these signals persist in the gut because of slow and prolonged release, satiety is enhanced.
- GLP-1 peptide tyrosine-tyrosine
- NT neurotensin
- ileal brake where unknown components in partly digested food reaches the distal small intestine and invokes a response in the form of secretion of the gut hormones GLP-1, PYY, NT and possibly others, as yet unknown hormones.
- GLP-1, PYY, NT and possibly others as yet unknown hormones.
- the precise mechanism behind the ileal brake is unknown.
- polypeptides of the invention may be used to treat conditions associated with a wide variety of metabolic diseases, for use in weight management, and/or for preventing or reducing the incidence of overweight and/or obesity, or for preventing or reducing cardiovascular diseases, atherosclerosis, hypertension, hepatosteatosis, cancer and/or diabetes.
- novel meat-derived polypeptides are superior in signalling of intestinal cell lines ( FIG. 3 ) and that only very specific peptides are capable of signalling ( FIG. 4 ).
- the inventors of the present invention have identified polypeptides including an octapeptide (ASDKPYIL, SEQ ID NO:6) present in proteolytic digests ( FIG. 5 ) and resistant to pepsin degradation, of which a pentapeptide (KPYIL, SEQ ID NO:9) is the minimal sequence with significant biologic activity ( FIG. 6 ).
- the octapeptide sequence is unique for the muscle-specific alpha-actinin-2 protein, and the sequence is conserved between all animal species. This peptide would be applicable as a novel, but natural nutritional supplement to induce satiation and satiety.
- the present invention relates to an isolated polypeptide comprising the amino acid sequence AA1-AA2-AA3-K-AA5-AA6-AA7-AA8 (formula I, SEQ ID NO:1), wherein AA1 is an optional amino acid selected from A, L, I, and V; AA2 is an optional amino acid selected from S, T, G, A, N, E and D; AA3 is an optional amino acid selected from D, E, and G; AA5 is selected from P, N, S, D, A, T, K, and G; AA6 is selected from Y, N, I, W, and F; AA7 is selected from I, L, R, and V; AA8 is selected from L, I, V, S, M, and T; which polypeptide is not more than 50 amino acids in length; or a variant thereof with a sequence identity of at least 80%.
- the present invention relates to an isolated polypeptide consisting of the amino acid sequence R1-AA1-AA2-AA3-K-AA5-AA6-AA7-AA8-R2 (formula II, SEQ ID NO:2), wherein AA1 is an optional amino acid selected from A, L, I, and V; AA2 is an optional amino acid selected from S, T, G, A, N, E and D; AA3 is an optional amino acid selected from D, E, and G; AA5 is selected from P, N, S, D, A, T, K, and G; AA6 is selected from Y, N, I, W, and F; AA7 is selected from I, L, R, and V; AA8 is selected from L, I, V, S, M, and T; R1 defines the N-term (—NH2) or a protection group; R2 defines the C-term (—COOH).
- AA1 is an optional amino acid selected from A, L, I, and V
- AA2 is an optional amino acid
- the present invention relates to a polypeptide having or comprising a sequence selected from ASDKPYIL (SEQ ID NO:6), SDKPYIL (SEQ ID NO:7), DKPYIL (SEQ ID NO:8), KPYIL (SEQ ID NO:9), AGDKNYIL (SEQ ID NO:10), AGDKNYIT (SEQ ID NO:11), AGDKSYIT (SEQ ID NO:12), ADGKPYIV (SEQ ID NO:13), AEDKDFIT (SEQ ID NO:14), AADKPYIL (SEQ ID NO:15), ATDKPYIL (SEQ ID NO:16), AGDKPYIT (SEQ ID NO:17), ASEKPYIL (SEQ ID NO:18), ADGKPYVT (SEQ ID NO:19), AGDKPYIL (SEQ ID NO:20), ASDKPNIL (SEQ ID NO:21), ASDKPYIT (SEQ ID NO:22), ASDKPY
- the present invention relates to a composition comprising a polypeptide of the invention.
- the present invention relates to a polypeptide according to the invention for use in promoting satiety in a subject, for use in weight management, and/or for preventing or reducing the incidence of overweight and/or obesity in a subject, or for preventing or reducing cardiovascular diseases, atherosclerosis, hypertension, hepatosteatosis, cancer and/or diabetes.
- the present invention relates to a method of preventing or reducing the incidence of obesity in a subject, and/or of promoting satiety in a subject, and/or to reduce or treat cardiovascular diseases, atherosclerosis, hypertension, hepatosteatosis, cancer and/or diabetes comprising enteral administering to a subject in need thereof a polypeptide comprising or consisting of the amino acid sequence AA1-AA2-AA3-AA4-AA5-AA6-AA7-AA8 (formula III, SEQ ID NO:3), wherein AA1 is an optional amino acid selected from A, L, I, and V; AA2 is an optional amino acid selected from S, T, G, A, N, E and D; AA3 is an optional amino acid selected from D, R, K, E, and G; AA4 is an amino acid selected from K and R; AA5 is selected from P, N, S, D, A, T, K, and G; AA6 is selected from Y, N, I,
- the present invention relates to a composition according to the invention for use in promoting satiety in a subject, and/or for use in weight management, and/or for preventing or reducing the incidence of obesity in a subject and/or for use in preventing or reducing cardiovascular diseases, atherosclerosis, hypertension, cardiovascular diseases, high blood pressure, cancer and/or diabetes.
- the present invention relates to a method of promoting satiety in a subject, and/or of preventing or reducing the incidence of obesity in a subject, and/or to reduce or treat cardiovascular diseases, atherosclerosis, hypertension, cardiovascular diseases, high blood pressure, cancer and/or diabetes, comprising administering to a subject in need thereof a composition according to the invention.
- FIG. 1 Dose-response curve for effect of protein hydrolysate on release of GLP-1 from GLUTag cells (open circles) or a control cell line (closed symbols) that does not produce GLP-1.
- Cells ( ⁇ 5 ⁇ 10 ⁇ 5 per sample) were incubated for up to 90 min in Dulbeccos Modified Eagle Medium (DMEM) containing 5.56 mM glucose in absence or presence of different amounts (weight/volume) of meat protein hydrolysate. Supernatant was filtered through 0.45 micron filters and assayed for content of GLP-1 as described in ELISA protocol. Data are mean+SEM from quadruplicate samples.
- DMEM Dulbeccos Modified Eagle Medium
- FIG. 2 Signaling by dietary nutrients in enteroendocrine cells. Illustration from Horm Res Paediatr. 2015; 83(1):1-10.
- FIG. 3 Stimulation of cell signaling (measured as increase in intracellular fluorescence) by meat protein hydrolysates (filled symbols) or whey protein hydrolysates (open symbols) in three different intestinal cell lines: Top) a murine intestinal cell line; middle) GLUTag cells; bottom) CaCo2 cells.
- FIG. 4 Size exclusion fractionation of protein hydrolysate and test of biologic activity. Absorbance at 280 nm shown by thick, solid line, activity of fractions by filled circles.
- FIG. 5 Verification of identified sequence ASDKPYIL by synthetic peptide. Comparison of dose-response relationship of meat hydrolysate and pure, synthetic peptide identified by sequencing of purified fractions.
- FIG. 6 Identification of minimal active sequence in ASDKPYIL in murine (mIC) and human (hIC) intestinal cells.
- Truncation from the amino-terminal or from the carboxy-terminal end of ASDKPYIL has different consequences. Deleting the carboxy-terminal leucine reduces potency more than two orders of magnitude in mIC cells and abrogates activity in hIC. Peptides with further deletions of 2, 3 or 4 amino acids from the carboxy-terminus are without activity. Deleting the first three amino acids from the amino-terminus has no big impact on activity. However, the fourth amino acid, lysine, is critical, since PYIL has two orders of magnitude lower activity compared with the full sequence in mIC and no activity in hIC. The following peptides are represented in FIG.
- PYIL (SEQ ID NO: 4), KPYIL (SEQ ID NO: 9), DKPYIL (SEQ ID NO: 8), SDKPYIL (SEQ ID NO: 7), ASDKPYIL (SEQ ID NO: 6), ASDKPYI (residues 1-7 of SEQ ID NO: 6), ASDKPYI (residues 1-6 of SEQ ID NO: 6), ASDKPY (residues 1-5 of SEQ ID NO: 6). ASDKP (residues 1-5 of SEQ ID NO: 6), ASDK (residues 1-4 of SEQ ID NO: 6).
- FIG. 7 Identification of critical residues in ASDKPYIL (SEQ ID NO: 6) (d-Ala (A D ) scan). Systematic replacement of all residues in ASDKPYIL (SEQ ID NO: 6) with the d-isomer of alanine and corresponding biological activity. Results show that 1) the last four amino acids (PYIL, SEQ ID NO:4) are critical, 2) replacing K reduces potency more than 30-fold, 3) replacing the aspartic residue improves potency almost 10-fold, and 4) alanine and serine on the first two positions are without importance.
- FIG. 8 Stability of peptides in rodent intestine. 0.001 mg/ml of the indicated peptides were incubated with pieces of rodent intestine (mouse and rat intestine gave similar results) for up to 10 minutes at 37 oC. Recovery of activity was tested with dose-response curves as indicated.
- the following peptides are represented in FIG. 8 : RRPYIL (SEQ ID NO: 39), DKPYIL (SEQ ID NO: 8), ASDKPYIL (SEQ ID NO: 6), AADKPYIL (SEQ ID NO: 15),
- FIG. 9 Stability of peptides in rodent intestine. EC50 values for different peptides and different incubation times were calculated from FIG. 8 and recovered activity plotted as a function of time. The following peptides are represented in FIG. 9 : ASDKPYIL (SEQ ID NO: 6), RRPYIL (SEQ ID NO: 39), DKPYIL (SEQ ID NO: 8). AADKPYIL (SEQ ID NO: 15).
- FIG. 10 Comparison of the sequences of three known gut hormones, neurotensin, neuromedin N (SEQ ID NO: 1010) and xenin (SEQ ID NO: 1011) with that of DC7-2 (ASDKPYIL, SEQ ID NO: 6).
- the PYIL (SEQ ID NO: 4) sequence is conserved, although Y is replaced by W in xenin.
- FIG. 11 Comparison of the DC7-2 sequence (aa 891-898) in isoforms of a-actinin 2 (Hs:Homo sapiens ACTN1 (SEQ ID NO: 1012); ACTN2 (SEQ ID NO: 1013); ACTN3 (SEQ ID NO: 1014); ACTN4 (SEQ ID NO: 1015)) and conservation between species (Dm: Drosophila melanogaster (DmACTN, SEQ ID NO: 1016); Ce: Caenorhabditis elegans (CeACTN, SEQ ID NO: 1017); Dd: Dictyostelium discoideum (DdACTN, SEQ ID NO: 1018); Sp: Schizosaccharomyces pombe (SpACTN, SEQ ID NO: 1019); Dr: Danio rerio).
- Hs Homo sapiens ACTN1 (SEQ ID NO: 1012); ACTN2 (SEQ ID NO: 1013); ACTN
- AGDKNYIT SEQ ID NO: 11
- AGDKNFIT SEQ ID NO: 27
- ASDKPYIL SEQ ID NO: 6
- AADKPYIL SEQ ID NO: 15
- ASGKTFIT SEQ ID NO: 1006
- AEDKDFIT SEQ ID NO: 14
- ADGKSYVT SEQ ID NO: 1007).
- FIG. 12 24 Balb/c female mice, 10-11 weeks, 20-22 g, were acclimatized to 12 h dark light cycle and placed single-housed in metabolic cages. Following administration of the indicated doses of DC7-2, feed and water intake was monitored for 6 h.
- FIG. 13 Summary of cell signaling activities of N-terminal substitutions in octa-, hepta-, hexa- and pentapeptides based on the sequence of DC7-2. Single-letter abbreviations for the 20 amino acids are shown on the plot centered at the corresponding EC50. The native amino acid in DC7-2 is marked with a grey circle for each of the peptides. The following peptides are represented in FIG. 13 : SDKPYIL (SEQ ID NO: 7), DKPYIL (SEQ ID NO: 8), KPYIL (SEQ ID NO: 9), PYIL (SEQ ID NO: 4).
- FIG. 14 Stability of DC7-2 families of peptides in intestine homogenates. Single-letter abbreviations for the 20 amino acids are shown on the plot with the corresponding stability expressed as the logarithm to the concentration of intestine homogenate that degrades half of the activity of peptide. All peptides were incubated at 10-5 M with various dilutions of a homogenate of the entire small intestine (pool from 20 mice). After incubation for 90 min at 37 oC, degradation was stopped by addition of 1 M phosphoric acid (final 0,4 M, pH ⁇ 1.2). Each peptide incubation mix was neutralized with NaOH and immediately tested for activity in intestinal cells. Control for zero degradation, i.e.
- FIG. 15 Stability of DC7-2 families of peptides in serum.
- the following peptides are represented in FIG. 15 : SDKPYIL (SEQ ID NO: 7).
- DKPYIL SEQ ID NO: 8
- KPYIL SEQ ID NO: 9
- PYIL SEQ ID NO: 4
- FIG. 16 Stability of X-KPYIL hexapeptides in intestine homogenate and serum.
- the following peptides are represented in FIG. 16 : KPYIL (SEQ ID NO: 9).
- FIG. 17 24 Balb/c female mice, 10-11 weeks, 20-22 g, were acclimatized to 12 h dark light cycle. Mice were divided into four groups each of six mice and placed single-housed in metabolic cages. Mice were then administered vehicle alone (day 1) for monitoring of feed and water intake for 6 h. On day 3, the same groups received the indicated doses of DC7-2, and feed and water intake was monitored for 6 h.
- FIG. 18 Swiss Webster male mice, 25-30 g, were acclimatized to 12 h dark/light cycle and placed single-housed in cages. Following administration just prior to onset of dark cycle of vehicle alone (0.5 ml of PBS w 1% of BSA) or vehicle+DC7-2, feed intake was monitored every hour for 6 h (during dark cycle). Mean and SEM from four experiments, each with 6-8 mice per treatment. Data were fitted with linear regression (R2>0.99) and 95% confidence intervals are shown as grey lines. Accumulated feed intake for treatment with DC7-2 was 64%+/ ⁇ 5% compared with control for these four experiments.
- FIG. 19 Swiss Webster male mice, 25-30 g, were acclimatized to 12 h dark/light cycle and placed single-housed in cages. Following administration just prior to onset of dark cycle of vehicle alone (0.5 ml of PBS w 1% of BSA) or vehicle+DC7-2, feed intake was monitored every hour for 12 h (during dark cycle) and then intermittently up to 30 h.
- vehicle alone 0.5 ml of PBS w 1% of BSA
- vehicle+DC7-2 feed intake was monitored every hour for 12 h (during dark cycle) and then intermittently up to 30 h.
- FIG. 20 Swiss Webster male (25-30 g) or female (20-25 g) mice were acclimatized to 12 h dark/light cycle and placed in groups of 6-8 mice per cage.
- Vehicle 0.5 ml of PBS w 1% of BSA
- vehicle+DC7-2 was administered three times per day (08:00; 16:00; 24:00), and feed intake was monitored daily for a week.
- Data were fitted with linear regression (R2>0.99) and 95% confidence intervals (grey lines).
- the inventors of the present invention have found novel polypeptides that may be used to induce signalling in intestinal cells and may consequently induce satiety.
- a specific peptide has been identified from a proteolytic digest of muscle-specific alpha-actinin-2 protein, it is envisioned that similar polypeptides will bind the same receptors in the intestine and provide the same biological activity, i.e. signal to induce satiation and satiety.
- Similar peptides may contain e.g. conservative substitutions or be truncated.
- the rationale for using the polypeptides of the invention is that the energy content due to the relatively small length of the peptide is low as compared to the effect on satiety.
- the first 1, 2, or 3 amino acids in the N-terminal of the amino acid sequences according to the invention are in the D-form. It is assumed that the N-terminal trimming and thereby degradation of the peptides are somewhat delayed by having amino acids of the D-form in the N-terminal of these polypeptides.
- the first 1, 2, or 3 amino acids in the N-terminal of the amino acid sequences according to the invention are amino acids in beta or gamma forms. Beta amino acids have their amino group bonded to the beta carbon rather than the alpha carbon as in the 20 standard natural amino acids.
- a capital D-letter subscript after the letter representing the amino acid residue designate herein amino acids specified to be in D-form such as W D referring to a tryptophan in D-form.
- a capital L-letter subscript after the letter representing the amino acid residue designate herein amino acids specified to be in L-form such as W L referring to a tryptophan in L-form. If not otherwise indicated, an amino acid is in its natural L-form.
- the first 1, 2, or 3 amino acids in the N-terminal of the amino acid sequences according to the invention may be modified by incorporation of protective groups, e.g. fluorine, or alternatively cyclic amino acids or other suitable non-natural amino acids are used.
- protective groups e.g. fluorine, or alternatively cyclic amino acids or other suitable non-natural amino acids are used.
- a “variant” or “analogue” of a peptide refers to a peptide having an amino acid sequence that is substantially identical to a reference peptide, typically a native or “parent” polypeptide, or a polypeptide of formula I or II.
- the peptide variant may possess one or more amino acid substitutions, deletions, and/or insertions at certain positions within the native amino acid sequence.
- the “variant” within this definition still has functional activity.
- a variant has at least 80% sequence identity with the reference polypeptide.
- a variant has at least 85% sequence identity with the reference polypeptide.
- a variant has at least 90% sequence identity with the reference polypeptide.
- a variant has at least 95% sequence identity with the reference polypeptide.
- “Conservative” amino acid substitutions are those in which an amino acid residue is replaced with an amino acid residue having a side chain with similar physicochemical properties. Families of amino acid residues having similar side chains are known in the art, and include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine, tryptophan), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine
- a particular form of conservative amino acid substitutions include those with amino acids, which are not among the normal 20 amino acids encoded by the genetic code. Since preferred embodiments of the present invention entail use of synthetic peptides, it is unproblematic to provide such “non-naturally occurring” amino acid residues in the peptides disclosed herein, and thereby it is possible to exchange the natural saturated carbon chains in the side chains of amino acid residues with shorter or longer saturated carbon chains—for instance, lysine may be substituted with an amino acid having a side chain —(CH2)nNH3, where n is different from 4, and arginine may be substituted with an amino acid having the side chain (CH2)nNHC( ⁇ NH2)NH2, where n is different from 3, etc. Similarly, the acidic amino acids aspartic acid and glutamic acid may be substituted with amino acid residues having the side chains —(CH2)nCOOH, where n>2.
- polypeptides of this invention may in some embodiments benefit from having higher stability than polypeptides containing only naturally occurring amino acids, and its modification enables to have much higher stability, such as a modification in the N-terminal of the polypeptide.
- the polypeptides of this invention have at their N-terminal a protection group, such as a protection group selected from the group consisting of acetyl group, fluorenyl methoxy carbonyl group, formyl group, palmitoyl group, myristyl group, stearyl group and polyethylene glycol (PEG).
- a protection group selected from the group consisting of acetyl group, fluorenyl methoxy carbonyl group, formyl group, palmitoyl group, myristyl group, stearyl group and polyethylene glycol (PEG).
- the active peptide may also be di- or multimerized, e.g. through cross-linking with suitable di- or multivalent chemical cross-linkers, e.g. disuccinimidyl suberate, containing spacers of different length, e.g. 10-100 ⁇ , and different functionality, e.g. homo- or heterofunctional, for coupling through non-critical amino or other reactive groups.
- suitable di- or multivalent chemical cross-linkers e.g. disuccinimidyl suberate
- spacers e.g. 10-100 ⁇
- different functionality e.g. homo- or heterofunctional
- photoactivation or enzymatic cross-linking may be used to increase stability and potency in vivo.
- stability refers to in vivo stability, such as the stability in the gut of a subject receiving such polypeptide.
- the protection group described above protects the peptides from the attack of protease in vivo.
- polypeptides according to the invention may be derived from a proteolytic digests of meat and be resistant to pepsin degradation. Accordingly, in some embodiments a polypeptide according to the invention may only contain naturally occurring amino acids.
- a polypeptide according to the invention is more stable towards degradation in the gastrointestinal tract, e.g. as measured in a stability assay described in the examples of the present invention, as compared to a control peptide. In some embodiments, a polypeptide according to the invention is more stable towards degradation in the gastrointestinal tract, e.g. measured in a stability assay described in the examples of the present invention as compared to a control peptide with the sequence RRPYIL, (SEQ ID NO:39).
- a polypeptide according to the invention has an half-life (T1 ⁇ 2) of degradation in vivo in the gut or in vitro, e.g. measured in a stability assay described in the example 2 of the present invention, which is higher than 2 min, such as higher than 4 min, such as higher than 6 min, such as higher than 8 min, such as higher than 10 min, such as higher than 15 min, such as higher than 20 min, such as higher than 25 min, such as higher than 30 min, such as higher than 35 min, such as higher than 40 min, such as higher than 45 min, such as higher than 50 min, such as higher than 55 min, such as higher than 60 min.
- T1 ⁇ 2 half-life of degradation in vivo in the gut or in vitro, e.g. measured in a stability assay described in the example 2 of the present invention, which is higher than 2 min, such as higher than 4 min, such as higher than 6 min, such as higher than 8 min, such as higher than 10 min, such as higher than 15 min, such as higher than 20 min,
- substantially identical in the context of two amino acid sequences means that the sequences, when optimally aligned, such as by the programs GAP or BESTFIT using default gap weights, share at least about 50, at least about 60, at least about 70, at least about 80, at least about 90, at least about 95, at least about 98, or at least about 99 percent sequence identity.
- a gap of one or two amino acids is allowed when the two peptide sequences are aligned without having any influence on the value of sequence identity.
- a residue position that is not identical differ by only a conservative amino acid substitution. Sequence identity is typically measured using sequence analysis software.
- Protein analysis software matches similar sequences using measures of similarity assigned to various substitutions, deletions and other modifications, including conservative amino acid substitutions.
- the publicly available GCG software contains programs such as “Gap” and “BestFit” which can be used with default parameters to determine sequence homology or sequence identity between closely related polypeptides, such as homologous polypeptides from different species of organisms or between a wild-type protein and a mutein thereof. See, e.g., GCG Version 6.1. Polypeptide sequences can also be compared using FASTA or ClustalW, applying default or recommended parameters.
- FASTA e.g., FASTA2 and FASTA3
- FASTA2 and FASTA3 provides alignments and percent sequence identity of the regions of the best overlap between the query and search sequences (Pearson, Methods Enzymol. 1990; 183:63-98; Pearson, Methods Mol. Biol. 2000; 132:185-219).
- Another preferred algorithm when comparing a sequence to a database containing a large number of sequences from various organisms is the computer program BLAST, especially blastp, using default parameters. See, e.g., Altschul et al., J. Mol. Biol. 1990; 215:403-410; Altschul et al., Nucleic Acids Res. 1997; 25:3389-402 (1997); each herein incorporated by reference.
- “Corresponding” amino acid positions in two substantially identical amino acid sequences are those aligned by any of the protein analysis software mentioned herein, typically using default parameters.
- the term “functional activity” as used herein refers to a polypeptide that stimulates cell signalling measured as fluorescence by elevated intracellular calcium or cellular release of gut hormones, such as measured in the signalling assays described in the examples.
- the functional activity of a variant may exhibit at least about 25%, such as at least about 50%, such as at least about 75%, such as at least about 90% of the specific activity of a reference polypeptide, such as the octapeptide ASDKPYIL, when tested in the assays as described herein.
- the functional activity of a variant may exhibit higher activity than a reference polypeptide, such as the octapeptide ASDKPYIL, when tested in the assays as described herein.
- an “isolated” molecule is a molecule that is the predominant species in the composition wherein it is found with respect to the class of molecules to which it belongs (i.e., it makes up at least about 5% of the type of molecule in the composition and typically will make up at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or more of the species of molecules, e.g., peptides, in the composition).
- a composition of a specific peptide sequence may exhibit 90%-99% homogeneity for peptides in the context of all present peptide species in the composition or at least with respect to substantially active peptide species in the context of proposed use. If produced synthetically, a composition of a specific peptide sequence will exhibit 98%-99%, or even higher and close to 100% homogeneity for peptides in the context of all present peptide species in the composition or at least with respect to substantially active peptide species in the context of proposed use.
- polypeptides within the present invention is a linear sequence of amino acids.
- linear sequence refers to the specific sequence of amino acids connected by standard peptide bonds in standard N- to C-terminal direction.
- the peptide may contain only peptide bonds.
- a second part of a peptide sequence may be bound to and continue from the side chain of a terminal amino acid in a first part of an amino acid sequence.
- an amino acid within a sequence such as within AA1-AA8 may be connected, such as through the side chains, with another amino acid at a distant location within the peptide sequence, such as a distant location within AA1-AA8.
- treatment refers to preventing, alleviating, managing, curing or reducing one or more symptoms or clinically relevant manifestations of a disease or disorder, unless contradicted by context.
- “treatment” of a patient in whom no symptoms or clinically relevant manifestations of a disease or disorder have been identified is preventive or prophylactic therapy
- “treatment” of a patient in whom symptoms or clinically relevant manifestations of a disease or disorder have been identified generally does not constitute preventive or prophylactic therapy.
- patient and “subject” refer to any human or animal that may be treated using the methods of the present invention.
- polypeptides or compositions to promote satiety in a subject.
- By inducing or promoting satiety in a subject such total amounts of calories, including calories derived from fat and carbohydrates are reduced in the subject.
- the polypeptides and compositions of the invention may be used in preventing or reducing a metabolic syndrome or disorder, such as obesity, insulin-deficiency or insulin-resistance related disorders, Diabetes Mellitus (such as, for example, Type 2 Diabetes), glucose intolerance, abnormal lipid metabolism, atherosclerosis, hypertension, cardiac pathology, stroke, non-alcoholic fatty liver disease, hyperglycemia, hepatic steatosis, dyslipidemia, dysfunction of the immune system associated with overweight and obesity, cardiovascular diseases, high cholesterol, elevated triglycerides, asthma, sleep apnoea, osteoarthritis, neuro-degeneration, gallbladder disease, syndrome X, inflammatory and immune disorders, atherogenic dyslipidemia and cancer.
- a metabolic syndrome or disorder such as obesity, insulin-deficiency or insulin-resistance related disorders, Diabetes Mellitus (such as, for example, Type 2 Diabetes), glucose intolerance, abnormal lipid metabolism, atherosclerosis, hypertension, cardiac pathology, stroke, non
- the invention also relates to a method of preparing polypeptides of the invention as mentioned above.
- the method of synthesis or preparation thereof includes, but is not limited to recombinant (whether produced from cDNA, genomic DNA, synthetic DNA or other form of nucleic acid), synthetic, and transgenic means.
- polypeptides of the invention described herein may be produced by means of recombinant nucleic acid techniques.
- a nucleic acid sequence encoding the desired polypeptide is then inserted into an expression vector, which is in turn transformed or transfected into host cells.
- the polypeptides of the invention are produced by synthetic means, i.e. by polypeptide synthesis.
- the invention relates to a method of manufacturing an analogue comprising non-natural amino acids from about 5 total residues to about 20 total residues.
- an analogue comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 non-natural amino acids, such as any one of the following non-naturally occurring amino acid residues.
- the polypeptides of the present invention can also comprise non-naturally occurring amino acid residues.
- Non-naturally occurring amino acids include, without limitation, beta-alanine, desaminohistidine, trans-3-methylproline, 2,4-methanoproline, cis-4-hydroxyproline, trans-4-hydroxyproline, N-methylglycine, allo-threonine, methylthreonine, hydroxyethylcys-teine, hydroxyethylhomocysteine, nitroglutamine, homoglutamine, pipecolic acid, thiazolidine carboxylic acid, dehydroproline, 3- and 4-methylproline, 3,3-dimethylproline, tert-leucine, nor-valine, 2-azaphenylalanine, 3-azaphenylalanine, 4-azaphenylalanine, and 4-fluorophenylalanine.
- coli cells are cul-tured in the absence of a natural amino acid that is to be replaced (e.g., phenylalanine) and in the presence of the desired non-naturally occurring amino acid(s) (e.g., 2-azaphenylalanine, 3-azaphenylalanine, 4-azaphenylalanine, or 4-fluorophenylalanine).
- the non-naturally occurring amino acid is incorporated into the polypeptide in place of its natural counterpart. See, Koide et al., Biochem. 33:7470-6, 1994.
- Naturally occurring amino acid residues can be converted to non-naturally occurring species by in vitro chemical modification. Chemical modification can be combined with site-directed mutagenesis to further expand the range of substitutions (Wynn and Richards, Protein Sci. 2:395-403, 1993).
- polypeptides of the invention may be purified from any natural source containing such polypeptide, such as from the proteolytic hydrolysate of muscle tissue, such as any source containing alpha-actinin-2 protein, such as by the methods described in the example section.
- sequence of the polypeptides of the invention is derived from a sequence found in nature, such as a fragment of alpha-actinin-2 protein.
- polypeptides of the present invention may be purified by a variety of procedures known in the art including, but not limited to, chromatography (e.g., ion exchange, affinity, hydrophobic, chromatofocusing, and size exclusion), electrophoretic procedures (e.g., preparative isoelectric focusing (IEF), differential solubility (e.g., ammonium sulfate precipitation), or extraction (see, e.g., Protein Purification, J.-C. Janson and Lars Ryden, editors, VCH Publishers, New York, 1989). They may be purified by affinity chromatography on an antibody column. Additional purification may be achieved by conventional chemical purification means, such as high performance liquid chromatography. Other methods of purification, including barium citrate precipitation, are known in the art, and may be applied to the purification—see, for example, Scopes, R., Protein Purification, Springer-Verlag, N.Y., 1982.
- the concentration of a specific peptide of the invention the higher is the effect in terms of inducing satiation and satiety relative to amount of total protein and total amount of calories consumed by the subject receiving the composition of polypeptides. It is to be understood that the idea of the invention is to administer polypeptides that induce satiation or satiety without administering a lot of calories to the subject.
- compositions of polypeptides of the invention are substantially pure.
- the polypeptides of the invention are purified to at least about 90 to 95% homogeneity, preferably to at least about 98% homogeneity.
- Purity may be assessed by e.g. HPLC and amino-terminal amino acid sequencing.
- Administration of the polypeptides according to the invention may be through several routes of administration, for example, lingual, sublingual, buccal, in the mouth, oral, in the stomach and intestine, nasal, pulmonary, for example, through the bronchioles and alveoli or a combination thereof, epidermal, dermal, transdermal, vaginal, rectal, ocular, for examples through the conjunctiva, uretal, and parenteral to patients in need of such a treatment.
- routes of administration for example, lingual, sublingual, buccal, in the mouth, oral, in the stomach and intestine, nasal, pulmonary, for example, through the bronchioles and alveoli or a combination thereof, epidermal, dermal, transdermal, vaginal, rectal, ocular, for examples through the conjunctiva, uretal, and parenteral to patients in need of such a treatment.
- polypeptides are derived from a source that naturally has to pass through the mouth and to the intestinal mucosa.
- compositions of the current invention may be administered in several dosage forms, for example, as solutions, suspensions, emulsions, microemulsions, multiple emulsion, foams, salves, pastes, plasters, ointments, tablets, coated tablets, rinses, capsules, for example, hard gelatine capsules and soft gelatine capsules, suppositories, rectal capsules, drops, gels, sprays, powder, aerosols, inhalants, eye drops, ophthalmic ointments, ophthalmic rinses, vaginal pessaries, vaginal rings, vaginal ointments, injection solution, in situ transforming solutions, for example in situ gelling, in situ setting, in situ precipitating, in situ crystallization, infusion solution, and implants.
- solutions for example, suspensions, emulsions, microemulsions, multiple emulsion, foams, salves, pastes, plasters, ointments, tablets, coated tablets, rinses,
- the appropriate dosage of the compositions and pharmaceutical compositions may vary depending on the individual being treated and the purpose. For example, the age, body weight, and medical history of the individual patient may affect the therapeutic efficacy of the therapy. Further, a lower dosage of the composition may be needed to produce a transient cessation of symptoms, while a larger dose may be needed to produce a complete cessation of symptoms associated with the disease, disorder, or indication. A competent physician can consider these factors and adjust the dosing regimen to ensure the dose is achieving the desired therapeutic outcome without undue experimentation. It is also noted that the clinician and/or treating physician will know how and when to interrupt, adjust, and/or terminate therapy in conjunction with individual patient response. Dosages may also depend on the strength of the particular polypeptide of the invention chosen for the pharmaceutical composition.
- the dose of the composition or pharmaceutical compositions may vary.
- the dose of the composition may be once per day. In some embodiments, multiple doses may be administered to the subject per day.
- the total dosage is administered in at least two application periods, In some embodiments, the period can be an hour, a day, a month, a year, a week, or a two-week period. In an additional embodiment of the invention, the total dosage is administered in two or more separate application periods, or separate doses.
- subjects can be administered the composition in which the composition is provided in a daily dose range of about 0.0001 mg/kg to about 5000 mg/kg of the weight of the subject.
- the dose administered to the subject can also be measured in terms of total amount of polypeptide of the invention administered per day.
- a subject is administered from about 0.001 to about 3000 milligrams of polypeptide of the invention per day.
- a subject is administered up to about 2000 milligrams of polypeptide of the invention per day.
- a subject is administered up to about 1800 milligrams of polypeptide of the invention per day.
- a subject is administered up to about 1600 milligrams of polypeptide of the invention per day.
- a subject is administered up to about 1400 milligrams of polypeptide of the invention per day. In some embodiments, a subject is administered up to about 1200 milligrams of polypeptide of the invention per day. In some embodiments, a subject is administered up to about 1000 milligrams of polypeptide of the invention per day. In some embodiments, a subject is administered up to about 800 milligrams of polypeptide of the invention per day. In some embodiments, a subject is administered from about 0.001 milligrams to about 700 milligrams of polypeptide of the invention per dose. In some embodiments, a subject is administered up to about 700 milligrams of polypeptide of the invention per dose.
- a subject is administered up to about 600 milligrams of polypeptide of the invention per dose. In some embodiments, a subject is administered up to about 500 milligrams of polypeptide of the invention per dose. In some embodiments, a subject is administered up to about 400 milligrams of polypeptide of the invention per dose. In some embodiments, a subject is administered up to about 300 milligrams of polypeptide of the invention per dose. In some embodiments, a subject is administered up to about 200 milligrams of polypeptide of the invention per dose. In some embodiments, a subject is administered up to about 100 milligrams of polypeptide of the invention per dose. In some embodiments, a subject is administered up to about 50 milligrams of polypeptide of the invention per dose.
- a composition, wherein a polypeptide of the invention is added may be any food composition, food product, or food ingredient.
- the term “food” is used in a broad sense—and covers food for humans as well as food for animals (i.e. a feed).
- the food is for human consumption.
- the food may be in the form of a solution or as a solid—depending on the use and/or the mode of application and/or the mode of administration.
- composition of the present invention may be used in conjunction with one or more of: a nutritionally acceptable carrier, a nutritionally acceptable diluent, a nutritionally acceptable excipient, a nutritionally acceptable adjuvant, a nutritionally active ingredient.
- composition of the present invention may be used as a food ingredient.
- the term “food ingredient” includes a formulation which is or can be added to functional foods or foodstuffs as a nutritional supplement.
- the term food ingredient as used here also refers to formulations which can be used at low levels in a wide variety of products that require gelling, texturising, stabilising, suspending, film-forming and structuring, retention of juiciness and improved mouthfeel, without adding viscosity.
- the food ingredient may be in the form of a solution or as a solid—depending on the use and/or the mode of application and/or the mode of administration.
- composition of the present invention may be—or may be added to—food supplements.
- composition of the present invention may be—or may be added to—functional foods.
- the term “functional food” means food which is capable of providing not only a nutritional effect and/or a taste satisfaction, but is also capable of delivering a further beneficial effect to consumer.
- functional foods are ordinary foods that have components or ingredients (such as those described herein) incorporated into them that impart to the food a specific functional—e.g. medical or physiological benefit—other than a purely nutritional effect.
- nutraceuticals Some functional foods are nutraceuticals.
- the term “nutraceutical” means a food which is capable of providing not only a nutritional effect and/or a taste satisfaction, but is also capable of delivering a therapeutic (or other beneficial) effect to the consumer. Nutraceuticals cross the traditional dividing lines between foods and medicine.
- composition of the present invention can be used in the preparation of or added to food products such as one or more of: jams, marmalades, jellies, dairy products (such as milk or cheese), meat products, poultry products, fish products, vegetable-based soups, and bakery products.
- food products such as one or more of: jams, marmalades, jellies, dairy products (such as milk or cheese), meat products, poultry products, fish products, vegetable-based soups, and bakery products.
- the composition of the present invention can be used as ingredients to soft drinks, a fruit juice or a beverage comprising whey protein, health teas, cocoa drinks, milk drinks and lactic acid bacteria drinks, yoghurt and drinking yoghurt, cheese, ice cream, water ices and desserts, confectionery, biscuits cakes and cake mixes, snack foods, breakfast cereals, instant noodles and cup noodles, instant soups and cup soups, balanced foods and drinks, sweeteners, texture improved snack bars, fibre bars, bake stable fruit fillings, care glaze, chocolate bakery filling, cheese cake flavoured filling, fruit flavoured cake filling, cake and doughnut icing, heat stable bakery filling, instant bakery filling creams, filing for cookies, ready-to-use bakery filling, reduced calorie filling, adult nutritional beverage, acidified soy/juice beverage, aseptic/retorted chocolate drink, bar mixes, beverage powders, calcium fortified soy/plaim and chocolate milk, calcium fortified coffee beverage.
- a composition according to the present invention can further be used as an ingredient in food products such as American cheese sauce, anti-caking agent for grated & shredded cheese, chip dip, cream cheese, dry blended whip topping fat free sour cream, freeze/thaw dairy whipping cream, freeze/thaw stable whipped topping, low fat & lite natural cheddar cheese, low fat Swiss style yoghurt, aerated frozen desserts, and novelty bars, hard pack ice cream, label friendly, improved economics & indulgence of hard pack ice cream, low fat ice cream: soft serve, barbecue sauce, cheese dip sauce, cottage cheese dressing, dry mix Alfredo sauce, mix cheese sauce, dry mix tomato sauce and others.
- food products such as American cheese sauce, anti-caking agent for grated & shredded cheese, chip dip, cream cheese, dry blended whip topping fat free sour cream, freeze/thaw dairy whipping cream, freeze/thaw stable whipped topping, low fat & lite natural cheddar cheese, low fat Swiss style yoghurt, aerated frozen desserts, and
- the foodstuff is a beverage.
- the foodstuff is a bakery product—such as bread, Danish pastry, biscuits or cookies.
- the present invention also provides a method of preparing a food or a food ingredient, the method comprising mixing a polypeptide according to the present invention or the composition according to the present invention with another food ingredient.
- One aspect of the invention related to an isolated polypeptide comprising the amino acid sequence AA1-AA2-AA3-K-AA5-AA6-AA7-AA8 (formula I, SEQ ID NO:1), wherein AA1 is an optional amino acid selected from A, L, I, and V; AA2 is an optional amino acid selected from S, T, G, A, N, E and D; AA3 is an optional amino acid selected from D, E, and G; AA5 is selected from P, N, S, D, A, T, K, and G; AA6 is selected from Y, N, I, W, and F; AA7 is selected from I, L, R, and V; AA8 is selected from L, I, V, S, M, and T; which polypeptide is not more than 50 amino acids in length; or a variant thereof with a sequence identity of at least 80%.
- Another aspect of the invention related to a method of promoting satiety in a subject or to a method of preventing or reducing the incidence of obesity in a subject comprising enteral administering to a subject in need thereof a polypeptide comprising or consisting of the amino acid sequence AA1-AA2-AA3-AA4-AA5-AA6-AA7-AA8 (formula III, SEQ ID NO:3), wherein AA1 is an optional amino acid selected from A, L, I, and V; AA2 is an optional amino acid selected from S, T, G, A, N, E and D; AA3 is an optional amino acid selected from D, R, K, E, and G; AA4 is an amino acid selected from K and R; AA5 is selected from P, N, S, D, A, T, K, and G; AA6 is selected from Y, N, I, W, and F; AA7 is selected from I, L, R, and V; AA8 is selected from L, I, V, S, M
- AA1-AA8 may refer to the amino acids of either formula I, II, or III.
- AA1 is absent. In some embodiments AA1 is any one natural amino acid selected from Y, W, V, T, S, R, Q, P, N, M, L, K, I, H, G, F, E, D, C, and A. In some embodiments AA2 is absent. In some embodiments AA2 is any one natural amino acid selected from Y, W, V, T, S, R, Q, P, N, M, L, K, I, H, G, F, E, D, C, and A. In some embodiments AA3 is absent. In some embodiments AA1 is present. In some embodiments AA2 is present. In some embodiments AA3 is present. In some embodiments AA1 is A.
- AA2 is S. In some embodiments AA3 is D. In some embodiments AA3 is selected from any one amino acid C, D, E, N, P, and Q. In some embodiments AA3 is selected from E and G. In some embodiments AA3 is P. In some embodiments AA3 is C. In some embodiments AA4 is K. In some embodiments AA6 is Y. In some embodiments AA7 is I. In some embodiments AA8 is L. In some embodiments the amino acid sequence is not found in nature. In some embodiments AA8 is the C-terminal amino acid. In some embodiments AA5 is P. In some embodiments AA6 is selected from Y and W. In some embodiments AA7 is selected from I and L.
- AA2 is an optional amino acid selected from S, T, A, N, E and D.
- AA5 is selected from P, S, D, A, T, K, and G.
- AA6 is selected from Y, N, I, and W.
- AA8 is selected from L, I, V, S, and M.
- the polypeptide does not comprise any one of the sequences AVTEKKYILYDFSVTS (SEQ ID NO:5), PRRPYIL (SEQ ID NO:38), RRPYIL (SEQ ID NO:39), RPYIL (SEQ ID NO:40), RRPWIL (SEQ ID NO:41), KRPYIL (SEQ ID NO:42), KKPYIL (SEQ ID NO:43), Adamantoyl-KPYIL (SEQ ID NO:9), H-Lys-psi(CH 2 NH)Lys-Pro-Tyr-Ile-Leu-OH (SEQ ID NO:44).
- the polypeptide does not comprise derivatives of Lys.
- the polypeptide does not consists of any one of the sequences AVTEKKYILYDFSVTS (SEQ ID NO:5), PRRPYIL (SEQ ID NO:38), RRPYIL (SEQ ID NO:39), RPYIL (SEQ ID NO:40), RRPWIL (SEQ ID NO:41), KRPYIL (SEQ ID NO:42), KKPYIL (SEQ ID NO:43), Adamantoyl-KPYIL(SEQ ID NO:9), H-Lys-psi(CH 2 NH) Lys-Pro-Tyr-Ile-Leu-OH (SEQ ID NO:44).
- the polypeptide is not a derivative of KPYIL (SEQ ID NO:9).
- the amino acid sequence only contains natural amino acids.
- the polypeptide of the invention is 5-50, such as 5-50, 5-49, 5-48, 5-47, 5-46, 5-45, 5-44, 5-43, 5-42, 5-41, 5-40, 5-39, 5-38, 5-37, 5-36, 5-35, 5-34, 5-33, 5-32, 5-31, 5-30, 5-29, 5-28, 5-27, 5-26, 5-25, 5-24, 5-23, 5-22, 5-21, 5-20, 5-19, such as 5-18, such as 5-17, such as 5-16, such as 5-15, such as 5-14, such as 5-13, such as 5-12, such as 5-11, such as 5-10, such as 5-9, such as 5-8, such as 5-7, such as 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 amino acids in length.
- polypeptide of the invention is less than 50, 49, 48, 47, 46, 45, 44, 43, 42, 41, 40, 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, such as 18, such as 17, such as 16, such as 15, such as 14, such as 13, such as 12, such as 11, such as 10, such as 9, such as 8, such as 7 amino acids in length.
- the polypeptide of the invention is 5-50, such as 6-50, such as 7-50, such as 8-50, such as 9-50, such as 10-50, such as 11-50, such as 12-50, such as 13-50, such as 14-50, such as 15-50, such as 16-50, such as 17-50, such as 18-50, such as 19-50, such as 20-50, such as 21-50, such as 22-50, such as 23-50, such as 24-50, such as 25-50, such as 26-50, such as 27-50, such as 28-50, such as 29-50, such as 30-50, such as 31-50, such as 32-50, such as 33-50, such as 34-50, such as 35-50, such as 36-50, such as 37-50, such as 38-50, such as 39-50, such as 40-50, such as 41-50, such as 42-50, such as 43-50, such as 44-50, such as 45-50, such as 46-50, such as 47-50, such as 48-50, such as 49-50 amino acids in length.
- the polypeptide of the invention is more than 5, such as 6, such as 7, such as 8, such as 9, such as 10, such as 11, such as 12, such as 13, such as 14, such as 15, such as 16, such as 17, such as 18, such as 19, such as 20, such as 21, such as 22, such as 23, such as 24, such as 25, such as 26, such as 27, such as 28, such as 29, such as 30, such as 31, such as 32, such as 33, such as 34, such as 35, such as 36, such as 37, such as 38, such as 39, such as 40, such as 41, such as 42, such as 43, such as 44, such as 45, such as 46, such as 47, such as 48, such as more than 49 amino acids in length.
- polypeptide of the invention has or comprises a sequence selected from ASDKPYIL (SEQ ID NO:6), SDKPYIL (SEQ ID NO:7), DKPYIL (SEQ ID NO:8), and KPYIL (SEQ ID NO:9).
- the polypeptide of the invention consist of or comprises a sequence selected from ASDKPYIL (SEQ ID NO:6), AGDKNYIL (SEQ ID NO:10), AGDKNYIT (SEQ ID NO:11), AGDKSYIT (SEQ ID NO:12), ADGKPYIV (SEQ ID NO:13), AEDKDFIT (SEQ ID NO:14), AADKPYIL (SEQ ID NO:15), ATDKPYIL (SEQ ID NO:16), AGDKPYIT (SEQ ID NO:17), ASEKPYIL (SEQ ID NO:18), ADGKPYVT (SEQ ID NO:19), AGDKPYIL (SEQ ID NO:20), ASDKPNIL (SEQ ID NO:21), ASDKPYIT (SEQ ID NO:22), AADKPFIL (SEQ ID NO:23), ASDKAYIT (SEQ ID NO:24), AGDKAYIT (SEQ ID NO:25), ANGKPFIT
- polypeptide of the invention is an isolated polypeptide.
- polypeptide of the invention is synthetically made.
- polypeptide of the invention is a purified fragment.
- polypeptide of the invention is purified from animal sources.
- polypeptide of the invention is generated by enzymatic treatment of proteins from animal sources.
- polypeptide of the invention has been modified by N terminal acylation or other chemical modifications to introduce protection groups.
- the polypeptide of the invention consists of or comprises an amino acid sequence selected from the group consisting of KPYIL, KPYII (SEQ ID NO:45), KPYIV (SEQ ID NO:46), KPYLL (SEQ ID NO:47), KPYLI (SEQ ID NO:48), KPYLV (SEQ ID NO:49), KPYVL (SEQ ID NO:50), KPYVI (SEQ ID NO:51), KPYVV (SEQ ID NO:52), KPWIL (SEQ ID NO:53), KPWII (SEQ ID NO:54), KPWIV (SEQ ID NO:55), KPWLL (SEQ ID NO:56), KPWLI (SEQ ID NO:57), KPWLV (SEQ ID NO:58), KPWVL (SEQ ID NO:59), KPWVI (SEQ ID NO:60), KPWVV (SEQ ID NO:61), RPYIL (SEQ ID NO:40),
- the polypeptide of the invention consist of or comprises an amino acid sequence selected from the group consisting of DKPYIL (SEQ ID NO:8), DKPYII (SEQ ID NO:79), DKPYIV (SEQ ID NO:80), DKPYLL (SEQ ID NO:81), DKPYLI (SEQ ID NO:82), DKPYLV (SEQ ID NO:83), DKPYVL (SEQ ID NO:84), DKPYVI (SEQ ID NO:85), DKPYVV (SEQ ID NO:86), DKPWIL (SEQ ID NO:87), DKPWII (SEQ ID NO:88), DKPWIV (SEQ ID NO:89), DKPWLL (SEQ ID NO:90), DKPWLI (SEQ ID NO:91), DKPWLV (SEQ ID NO:92), DKPWVL (SEQ ID NO:93), DKPWVI (SEQ ID NO:94), DK
- the polypeptide of the invention consists of or comprises an amino acid sequence selected from the group consisting of SDKPYIL (SEQ ID NO:220), SDKPYII (SEQ ID NO:221), SDKPYIV (SEQ ID NO:222), SDKPYLL (SEQ ID NO:223), SDKPYLI (SEQ ID NO:224), SDKPYLV (SEQ ID NO:225), SDKPYVL (SEQ ID NO:226), SDKPYVI (SEQ ID NO:227), SDKPYVV (SEQ ID NO:228), SDKPWIL (SEQ ID NO:229), SDKPWII (SEQ ID NO:230), SDKPWIV (SEQ ID NO:231), SDKPWLL (SEQ ID NO:232), SDKPWLI (SEQ ID NO:233), SDKPWLV (SEQ ID NO:234), SDKPWVL (SEQ ID NO:235), SDKPWVI
- the polypeptide of the invention consists of or comprises an amino acid sequence selected from the group consisting of ASDKPYII (SEQ ID NO:364), ASDKPYIV (SEQ ID NO:365), ASDKPYLL (SEQ ID NO:366), ASDKPYLI (SEQ ID NO:367), ASDKPYLV (SEQ ID NO:368), ASDKPYVL (SEQ ID NO:369), ASDKPYVI (SEQ ID NO:370), ASDKPYVV (SEQ ID NO:371), ASDKPWIL (SEQ ID NO:372), ASDKPWII (SEQ ID NO:373), ASDKPWIV (SEQ ID NO:374), ASDKPWLL (SEQ ID NO:375), ASDKPWLI (SEQ ID NO:376), ASDKPWLV (SEQ ID NO:377), ASDKPWVL (SEQ ID NO:378),
- the polypeptide of the invention consists of or comprises an amino acid sequence derived from Alpha-actinin-1, such as a sequence selected from ASDKPYIL (SEQ ID NO:6), AGDKNYIL (SEQ ID NO:10), AGDKNYIT (SEQ ID NO:11), AGDKSYIT (SEQ ID NO:12), ADGKPYIV (SEQ ID NO:13), and AEDKDFIT (SEQ ID NO:14).
- ASDKPYIL SEQ ID NO:6
- AGDKNYIL SEQ ID NO:10
- AGDKNYIT SEQ ID NO:11
- AGDKSYIT SEQ ID NO:12
- ADGKPYIV SEQ ID NO:13
- AEDKDFIT SEQ ID NO:14
- the polypeptide of the invention consists of or comprises an amino acid sequence derived from Alpha-actinin-2, such as a sequence selected from ASDKPYIL (SEQ ID NO:6), AADKPYIL (SEQ ID NO:15), AGDKNYIT (SEQ ID NO:11), ATDKPYIL (SEQ ID NO:16), AGDKPYIT (SEQ ID NO:17), ASEKPYIL (SEQ ID NO:18), ADGKPYVT (SEQ ID NO:19), AGDKPYIL (SEQ ID NO:20), ASDKPNIL (SEQ ID NO:21), ASDKPYIT (SEQ ID NO:22), AADKPFIL (SEQ ID NO:23), ASDKAYIT (SEQ ID NO:24), AGDKAYIT (SEQ ID NO:25), ANGKPFIT (SEQ ID NO:26), and AGDKNFIT (SEQ ID NO:27).
- ASDKPYIL SEQ ID NO:6
- the polypeptide of the invention consists of or comprises an amino acid sequence derived from Alpha-actinin-3, such as a sequence selected from ASDKPYIL (SEQ ID NO:6), AADKPYIL (SEQ ID NO:15), ASDKAYIT (SEQ ID NO:24), ASDKSYIT (SEQ ID NO:28), ASDKTYIT (SEQ ID NO:29), ASDKNYIT (SEQ ID NO:30), AGDKNYIL (SEQ ID NO:10), AGDKSYIT (SEQ ID NO:12), AGDKNYIT (SEQ ID NO:11), AGDKKYIT (SEQ ID NO:31), and AGDKNYIS (SEQ ID NO:32).
- ASDKPYIL SEQ ID NO:6
- AADKPYIL SEQ ID NO:15
- ASDKAYIT SEQ ID NO:24
- ASDKSYIT SEQ ID NO:28
- ASDKTYIT SEQ ID NO:29
- ASDKNYIT S
- the polypeptide of the invention consists of or comprises an amino acid sequence derived from Alpha-actinin-4, such as a sequence selected from ASDKPYIL (SEQ ID NO:6) , AGDKPYIL (SEQ ID NO:20), AADKNYIT (SEQ ID NO:33), AGDKNYIM (SEQ ID NO:34), AGDKNYIT (SEQ ID NO:11), AADKNFIM (SEQ ID NO:35), AADKNFIT (SEQ ID NO:36), AGDKGIRS (SEQ ID NO:37), and AGDKNFIT (SEQ ID NO:27).
- ASDKPYIL SEQ ID NO:6
- AGDKPYIL SEQ ID NO:20
- AADKNYIT SEQ ID NO:33
- AGDKNYIM SEQ ID NO:34
- AGDKNYIT SEQ ID NO:11
- AADKNFIM SEQ ID NO:35
- AADKNFIT SEQ ID NO:36
- AGDKGIRS
- the present invention further relates to compositions comprising the polypeptides of the invention.
- the compositions of the invention is capable of promoting satiety in a subject upon consumption.
- the amount of said polypeptide in the composition is less than about 10 g, such as less than 9 g, 8 g, 7 g, 6 g, 5 g, 4 g, 3 g, 2 g, 1 g, 900 mg, 800 mg, 700 mg, 600 mg, 500 mg, 400 mg, 300 mg, 200 mg, 150 mg, 100 mg, 90 mg, 80 mg, 70 mg, 60 mg, 50 mg, 40 mg, 30 mg, 25 mg, 20 mg, 15 mg, 10 mg, or 5 mg.
- the amount of said polypeptide in the composition is at least about 5 mg, such as at least about 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, 100 mg, 150 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 700 mg, 800 mg, 900 mg, 1 g, 2 g, 3 g, 4 g, 5 g, 6 g, 7 g, 8 g, 9 g, or 10 g.
- the energy content derived through the process of cellular respiration is less than 50 kilojoules (kJ), such as less than 40 kJ, such as less than 30 kJ, such as less than 20 kJ, such as less than 10 kJ, such as less than 5000 Joules (3), such as less than 1000 J, such as less than 900 J, such as less than 800 J, such as less than 700 J, such as less than 600 J, such as less than 500 J, such as less than 400 J, such as less than 300 J, such as less than 200 J, such as less than 100 J, such as less than 50 J.
- kJ kilojoules
- compositions of the invention is a food composition.
- compositions of the invention is a fermented composition.
- compositions of the invention is a dairy product.
- compositions of the invention is a pharmaceutical composition.
- compositions of the invention is a nutritional composition.
- compositions of the invention is an oral dosage form.
- the oral dosage form is selected from the group comprising tablets, capsules, caplets, slurries, sachets, suspensions, chewing gum, and powder formulation that may be dissolved in a liquid.
- the oral dosage form is a suspension.
- the oral dosage form is a powder formulation that may be dissolved in a liquid.
- the liquid is water, milk, juice, or yogurt.
- Elevation of intracellular calcium level was measured using the fluorescent calcium chelating dye Fluo-4 AM (ThermoFischer Scientific, Denmark). Briefly, cells were grown as a monolayer in 96-well tissue culture plates (Sarstedt, Germany) to near confluence in appropriate growth medium as described in the cell culture section.
- the cells Prior to the start of the assay, the cells were incubated with 1.5 ⁇ M Fluo-4 AM in complete culture media mixed 1:1 with Hank's balanced salt solution (HBSS, ThermoFischer Scientific, Denmark) containing 25 mM HEPES (pH 7.4), 1% BSA (Sigma-Aldrich, Denmark), 2% ink (Soluro GMBH, Germany), 0.01% Pluronic F-127 (Sigma-Aldrich, Denmark) and 1 mM Probenecide (Sigma-Aldrich) for 60 minutes at 37° C.
- HBSS Hank's balanced salt solution
- BSA Sigma-Aldrich, Denmark
- Pluronic F-127 Sigma-Aldrich, Denmark
- 1 mM Probenecide Sigma-Aldrich
- test compounds were dissolved in water, and then diluted in 1 ⁇ HBSS containing 25 mM HEPES (pH 7.4), 1% BSA and 2% ink. Without any removal of excess Fluo-4 AM, test compounds were added directly into the wells and fluorescence were measured using instrument settings for excitation at 488 nm and emission at 525 nm in a microtiter plate reader (SpectraMax M5, Molecular Devices, USA).
- Cell culture media Dulbecco's phosphate-buffered saline, pH 7.4 (DPBS), glutamine, trypsin-EDTA and antibiotics were obtained from ThermoFischer Scientific (Denmark). Fetal bovine serum and all other chemicals were purchased from Sigma-Aldrich (Denmark), unless otherwise stated.
- Murine intestinal enteroendocrine L-cell lines that expresses the proglucagon gene and secretes GLP-1 in vitro were used. Cells were grown in DMEM containing 1 g/L D-glucose, 10% fetal bovine serum, 2 mM glutamine, 1% penicillin/streptomycin/neomycin and cultured in a humidified incubator in 95% air and 5% CO2 at 37° C.
- DMEM Dulbecco's modified Eagle's medium
- Other murine intestinal cell lines were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 2 mM glutamine, 2.5 g/L glucose, 20 mM HEPES, 60 nM sodium selenite, 5 ⁇ g/ml transferrin, 5 ⁇ g/ml insulin, 50 nM dexamethasone, 10 nM EGF, 1 nM triiodothyronine, 2% fetal bovine serum and 1% penicillin/streptomycin/neomycin at 37° C. in 5% CO2-95% air atmosphere.
- DMEM Dulbecco's modified Eagle's medium
- Human intestinal cell lines were cultured in McCoy's modified 5A medium supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin/neomycin at 37° C. and 5% CO2 in a humidified incubator.
- GLP-1 levels were determined using a sandwich enzyme-linked immunoabsorbant assay (ELISA).
- the primary antibody to GLP-1 [2.5 ⁇ g/ml mouse monoclonal (HYB 147-06) in 0.05M bicarbonate/carbonate buffer; BioPorto Diagnostics A/S, Gentofte, Denmark) was coated on a flat-bottom 96-well plate (Sarstedt, Nümbrecht, Germany) for at least 24 hours at 4° C.
- This primary antibody is specific for the amidated C-terminus of the peptide and reacts with GLP-1 (7-36), GLP-1 (9-36) and GLP-1 (1-36), but not with GLP-1 (7-37).
- the plate was washed four times, and the wells were incubated with a secondary biotinylated antibody to GLP-1 [1 ⁇ g/ml; mouse monoclonal (ABS 033-01), BioPorto Diagnostics A/S, Gentofte, Denmark) for two hours at room temperature.
- a secondary biotinylated antibody to GLP-1 [1 ⁇ g/ml; mouse monoclonal (ABS 033-01), BioPorto Diagnostics A/S, Gentofte, Denmark) for two hours at room temperature.
- streptavidin-horseradish peroxidase (1:200, Dako A/S, Denmark) for 45 minutes followed by an incubation with TMB solution (containing 3,3′,5,′5-tetramethylbenzidine and H2O2, SMS- fate, Denmark).
- the reaction was stopped by adding H2SO4 (0.2M), and the absorbance of the yellow end product was measured at 450 nm on a microtiter plate spectrophotometer (SpectraMax M5, Molecular Devices, USA). The concentrations of the samples were determined by interpolation to the concentrations of the standard solutions.
- DMEM Dulbeccos Modified Eagle Medium
- Minced meat is diluted 1-10 times with distilled water, adjusted to pH 1-3 with hydrochloric acid, and incubated with 0.01-10% pepsin (w/w) at 4-40° C. for 1 ⁇ 2-12 h with adequate mixing.
- Insoluble material is removed by centrifugation at 100-1000 ⁇ g for 3-30 min, and supernatant is neutralized with NaOH.
- sterile conditions low molecular weight peptides in supernatant are recovered by tangential ultrafiltration at 4-40° C. for 1 ⁇ 2-12 h, and excess water is evaporated at 25-50° C. for up to 12 h.
- the concentrated dialysate is tested for bioactivity with cells and used for further purification by HPLC.
- Upconcentrated dialysates were fractionated on preparative C18 columns using buffer B: 20 mM phosphate buffer pH 8.25/10% ACN and a gradient of 0-40% in buffer A: 60% ACN in same buffer. Fractions were tested for bioactivity and further purified by isocratic elution using EVO C18 columns with 4.5% ACN in 0.1%FA isocratic for 30 min. Fractions were subject to MS characterization, where a dominating peak with m/z 453.75 (+2) was observed. Extracted ions chromatograms show this peak to be present in all active fractions. De novo sequencing of 453.75 peak gives [A]SDKPY[I,L][I,L].
- N-terminal A (e.g., SEQ ID NO: 6) is calculated from parent ion ⁇ A7. I and L are not resolved by MS because of equal molecular weights. Search of protein sequences gives only ASDKPYIL(SEQ ID NO: 6) as match. ASDKPYIL (SEQ ID NO: 6) is only found in alpha-actinin-2, a major muscle protein.
- Peptides are degraded by proteases in the gastrointestinal tract. However the speed of this degradation depends on the sequence of the peptide.
- ASDKPYIL SEQ ID NO: 6
- RRKPYIL SEQ ID NO: 1008
- 10 or 50 mg (wet weight) of mouse or rat intestinal tissue was equilibrated in V-bottom 24 well plates in 800 ⁇ l HBSS, 25 mM HEPES, pH 7,4 at 37 oC with shaking at 350 rpm.
- Identical amounts of different peptides final concentration of 1 ⁇ g/ml were added to the intestinal pieces and incubation continued.
- peptides being octapeptides, heptapeptides, hexapeptides, or pentapeptides to exhibit increased potency due to increased binding may be predicted.
- Protein concentration of synthetic peptides (Schafer-N, Denmark), NT (Sigma-Aldrich, Denmark) and NT (8-13)(Sigma-Aldrich, Denmark) were determined by measuring absorbance at 280 nm in Costar® 96-well UV-transparent plates (Corning, Sigma-Aldrich, Denmark). Each peptide was measured in 4 different concentrations by dilution in Hank's balanced salt solution (HBSS, ThermoFischer Scientific, Denmark) containing 25 mM HEPES (pH 7.4) (Sigma-Aldrich, Denmark). For stability assays, all peptides were diluted to 3 ⁇ 10 ⁇ 5 M in HBSS; 25 mM HEPES (Ph 7.4) and stored at +4° C.
- Small intestines from 20 Swiss-Webster males were homogenized in 350 ml Dulbecco's phosphate-buffered saline (PBS) (pH 7.4) (ThermoFischer Scientific, Denmark) with a IKA® basic 18 Ultra-Turrax tissue homogenizer set a speed 5 followed by filtration using 100 ⁇ m nylon mesh filter. Protein concentration was 6 mg/ml using the bicinconinic acid assay (ThermoFischer Scientific, Denmark) and bovine serum albumin as standard.
- PBS Dulbecco's phosphate-buffered saline
- IKA® basic 18 Ultra-Turrax tissue homogenizer set a speed 5 followed by filtration using 100 ⁇ m nylon mesh filter. Protein concentration was 6 mg/ml using the bicinconinic acid assay (ThermoFischer Scientific, Denmark) and bovine serum albumin as standard.
- the intestine homogenate was diluted 10 times in HBSS containing 25 mM HEPES (pH 7.4), and further diluted 30 ⁇ , 90 ⁇ , 270 ⁇ , 810 ⁇ or 2430 ⁇ before incubation with peptides. All solutions were prewarmed to 37° C. before mixing with peptide solutions.
- Peptides were incubated at 10 ⁇ 5 M with dilutions of small intestine homogenate at 37° C. for 90 minutes with shaking. Reactions were stopped by addition of 1 M phosphoric acid (final 0.4 M, pH ⁇ 1.2). Each peptide incubation mix was then neutralized with NaOH to pH 7.2-7.4 and immediately tested for activity in intestinal cells. Control for zero degradation, i.e. addition of 1 M phosphoric acid prior to addition of intestine homogenate, was included for each peptide.
- DC7-2, NT, DKPYIL (SEQ ID NO: 8) and NT-(8-13) were incubated either with FBS or with 270X diluted intestinal homogenate at 37° C. for various time points with shaking. Degradation was stopped with 1 M phosphoric acid and the samples were subsequently neutralized and immediately tested with intestinal cells as described above. Control for zero degradation was included for each peptide as above.
- the 20 hexapeptides with systematic N-terminal substitutions (X-KPYIL, SEQ ID NO: 9) (Schafer-N, Denmark) and NT (8-13) was incubated at 10-6 M in either FBS for 10 minutes or with 270X diluted intestinal homogenate for 30 minutes at 37° C. with shaking. The degradation was stopped with 1 M phosphoric acid. Peptide solutions were neutralized with NaOH (pH 7.2-7.4), diluted and immediately tested for bioactivity using murine intestinal cells. Determination of EC50 for stimulation of cells allowed calculation of recovered peptide.
- Stability in serum is expressed as fraction of peptide activity left after 10 min of incubation in serum at 37° C. compared with undigested sample as described in Examples.
- Stability in intestine is expressed as % activity left after 30 min incubation in intestine homogenate at 37° C. as described in Examples.
- DKPYIL As compared to the hexapeptide of a natural hormone, neurotensin (8-13) (NT with the sequence RRPYIL), one specific peptide of the present invention DKPYIL is nearly 100 times more stable in serum and around 100-1000 ⁇ more stable in intestine homogenate.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15200440 | 2015-12-16 | ||
EP15200440 | 2015-12-16 | ||
EP15200440.4 | 2015-12-16 | ||
PCT/EP2016/081572 WO2017103200A1 (en) | 2015-12-16 | 2016-12-16 | Dietary peptides |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2016/081572 A-371-Of-International WO2017103200A1 (en) | 2015-12-16 | 2016-12-16 | Dietary peptides |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/678,574 Division US20220248736A1 (en) | 2015-12-16 | 2022-02-23 | Dietary peptides |
Publications (2)
Publication Number | Publication Date |
---|---|
US20180368459A1 US20180368459A1 (en) | 2018-12-27 |
US11259554B2 true US11259554B2 (en) | 2022-03-01 |
Family
ID=55068774
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/062,429 Active US11259554B2 (en) | 2015-12-16 | 2016-12-16 | Dietary peptides |
US17/678,574 Pending US20220248736A1 (en) | 2015-12-16 | 2022-02-23 | Dietary peptides |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/678,574 Pending US20220248736A1 (en) | 2015-12-16 | 2022-02-23 | Dietary peptides |
Country Status (11)
Country | Link |
---|---|
US (2) | US11259554B2 (ja) |
EP (1) | EP3390425B1 (ja) |
JP (1) | JP7117779B2 (ja) |
KR (1) | KR20180087433A (ja) |
CN (1) | CN108473535A (ja) |
AU (1) | AU2016372510B2 (ja) |
BR (1) | BR112018012353A2 (ja) |
CA (1) | CA3007436A1 (ja) |
MX (1) | MX2018007212A (ja) |
RU (1) | RU2018125630A (ja) |
WO (1) | WO2017103200A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3938037A1 (en) * | 2019-03-15 | 2022-01-19 | Diet4Life ApS | Combination of dietary peptides |
WO2020187772A1 (en) * | 2019-03-15 | 2020-09-24 | Diet4Life Aps | Peptide constructs and compositions |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5846940A (en) | 1994-08-05 | 1998-12-08 | Sinseiro Okamoto | Corneal therapeutic agent |
WO2008001045A1 (en) | 2006-06-26 | 2008-01-03 | Ares Trading S.A. | Members of the glycoside hydrolase family 31 family of proteins |
WO2008074329A2 (en) | 2006-12-21 | 2008-06-26 | Neuronicon Aps | Modulation of activity of proneurotrophins |
US20090082265A1 (en) * | 2002-01-04 | 2009-03-26 | Myriad Genetics, Incorporated | Compositions and methods for treating diseases |
US20090117578A1 (en) | 2007-11-05 | 2009-05-07 | Battelle Memorial Institute | Method for identifying type I diabetes mellitus in humans |
KR20090112270A (ko) * | 2008-04-24 | 2009-10-28 | 대한민국(관리부서:농촌진흥청) | 한우 근육부위 판별용 바이오 마커 단백질 |
WO2010063124A1 (en) | 2008-12-05 | 2010-06-10 | Angiochem Inc. | Peptide therapeutic conjugates and uses thereof |
WO2011005893A2 (en) | 2009-07-07 | 2011-01-13 | Abbott Laboratories | Biomarkers and methods for detecting alzheimer's disease |
WO2011092473A1 (en) | 2010-01-27 | 2011-08-04 | Imperial Innovations Limited | Novel compounds and their effects on feeding behaviour |
WO2015048342A2 (en) | 2013-09-25 | 2015-04-02 | Pronutria, Inc. | Compositions and formulations for maintaining and increasing muscle mass, strength, and performance and methods of production and use thereof |
WO2017100700A2 (en) * | 2015-12-11 | 2017-06-15 | Fred Hutchinson Cancer Research Center | Peptides for renal therapy |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3938037A1 (en) * | 2019-03-15 | 2022-01-19 | Diet4Life ApS | Combination of dietary peptides |
WO2020187772A1 (en) * | 2019-03-15 | 2020-09-24 | Diet4Life Aps | Peptide constructs and compositions |
-
2016
- 2016-12-16 MX MX2018007212A patent/MX2018007212A/es unknown
- 2016-12-16 US US16/062,429 patent/US11259554B2/en active Active
- 2016-12-16 EP EP16823233.8A patent/EP3390425B1/en active Active
- 2016-12-16 BR BR112018012353A patent/BR112018012353A2/pt active Search and Examination
- 2016-12-16 RU RU2018125630A patent/RU2018125630A/ru unknown
- 2016-12-16 KR KR1020187020389A patent/KR20180087433A/ko not_active Application Discontinuation
- 2016-12-16 JP JP2018551497A patent/JP7117779B2/ja active Active
- 2016-12-16 CA CA3007436A patent/CA3007436A1/en active Pending
- 2016-12-16 WO PCT/EP2016/081572 patent/WO2017103200A1/en active Application Filing
- 2016-12-16 AU AU2016372510A patent/AU2016372510B2/en active Active
- 2016-12-16 CN CN201680079422.XA patent/CN108473535A/zh active Pending
-
2022
- 2022-02-23 US US17/678,574 patent/US20220248736A1/en active Pending
Patent Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5846940A (en) | 1994-08-05 | 1998-12-08 | Sinseiro Okamoto | Corneal therapeutic agent |
US20090082265A1 (en) * | 2002-01-04 | 2009-03-26 | Myriad Genetics, Incorporated | Compositions and methods for treating diseases |
WO2008001045A1 (en) | 2006-06-26 | 2008-01-03 | Ares Trading S.A. | Members of the glycoside hydrolase family 31 family of proteins |
WO2008074329A2 (en) | 2006-12-21 | 2008-06-26 | Neuronicon Aps | Modulation of activity of proneurotrophins |
US20090117578A1 (en) | 2007-11-05 | 2009-05-07 | Battelle Memorial Institute | Method for identifying type I diabetes mellitus in humans |
KR20090112270A (ko) * | 2008-04-24 | 2009-10-28 | 대한민국(관리부서:농촌진흥청) | 한우 근육부위 판별용 바이오 마커 단백질 |
WO2010063124A1 (en) | 2008-12-05 | 2010-06-10 | Angiochem Inc. | Peptide therapeutic conjugates and uses thereof |
WO2011005893A2 (en) | 2009-07-07 | 2011-01-13 | Abbott Laboratories | Biomarkers and methods for detecting alzheimer's disease |
WO2011092473A1 (en) | 2010-01-27 | 2011-08-04 | Imperial Innovations Limited | Novel compounds and their effects on feeding behaviour |
RU2012136530A (ru) | 2010-01-27 | 2014-03-10 | Империал Инновейшнс Лимитед | Новые соединения, влияющие на пищевое поведение |
WO2015048342A2 (en) | 2013-09-25 | 2015-04-02 | Pronutria, Inc. | Compositions and formulations for maintaining and increasing muscle mass, strength, and performance and methods of production and use thereof |
RU2016110800A (ru) | 2013-09-25 | 2017-10-30 | Пронутриа Биосайенсис, Инк. | Составы и композиции для поддержания и увеличения мышечной массы, силы и результативности, и способы их производства и использования |
WO2017100700A2 (en) * | 2015-12-11 | 2017-06-15 | Fred Hutchinson Cancer Research Center | Peptides for renal therapy |
Non-Patent Citations (15)
Title |
---|
"Food energy—methods of analysis and conversion factors", Chapter 3—Calculation of the energy content of foods—energy conversion factors. Food and Agriculture Organization of the United Nations, Rome. (Year: 2003). * |
Abiko, et anan, "Syntheses Of Neurotensin (NT) Analogues And Their Comparative Anorectic Effect On Food Intake In Rats," Protein and Peptide Letters, 2001, vol. 8(6) pp. 461-468. |
Cain et al. "identification of Simpler Analogs of Neurotesin(9-13) Which Retain Antinociceptive Activity" Bioorganic & Medicinal Chemistry Letters 3:1767-1772. (Year: 1993). * |
Cain, G., et al., "Identification Of Simpler Analogs Of Neurotensin(9-13) Which Retain Antinociceptive Activity," Bioorganic & Medicinal Chemistry Letters, 1993, vol. 3(8), pp. 1767-1772. |
Christos et al. "Stables Isosteres of Nerotensin C-terminal Pentapeptides Derived By Modifications of the Amide Function" Bioorganic & Medicinal Chemistry Letters 3:1035-1040. (Year: 1993). * |
Christos, T., et al., "Stable Isosteres Of Nerotensin C-Terminal Pentapeptides Derived By Modification Of the Amide Function," Bioorganic & Medicinal Chemistry Letters, 1993, vol. 3(6), pp. 1035-1040. |
Cusack et al. "Pharmacological and Biochemical Profiles of Unique Neurotensin 8-13 Analogs Exhibiting Species Selectivity, Stereoselectivity, and Superagonism" J. Biological Chemistry 270:18359-18366. (Year: 1995). * |
Cusack, B., et al., "Pharmacological and Biochemical Profiles of Unique Neurotensin 8-13 Analogs Exhibiting Species Selectivity, Stereoselectivity, and Superagonism," The Journal of Biological Chemistry, 1995, vol. 270(31), pp. 18359-18366. |
Einsiedel, J., et al., "Discovery of Highly Potent and Neurotensin Receptor 2 Selective Neurotensin Mimetics," Journal of Medicinal Chemistry, 2011, vol. 54, pp. 2915-2923. |
Einsiedel, J., et al., "Peptide backbone modifications on the C-terminal hexapeptide of neurotensin," Bioorganic & Medicinal Chemistry Letters, 2008, vol. 18, pp. 2013-2018. |
Neurotensin (8-13). Anaspec. Catalog #AS-22964. (Year: 2015). * |
Nguyen et al. Tap Chi Phan Tich Hoa 14:62-69. Abstract Only (Year: 2010). * |
Samson et al. "A 35 Amino Acid Fragment of Leptin Inhibits Feeding in the Rat" Endocrinology 137:5182-5185. (Year: 1996). * |
Samson, W., et al., "A 35 Amino Acid Fragment Of Leptin Inhibits Feeding In The Rat," Endocrinology, 1996, vol. 137(11), pp. 5182-5185. |
Zhao et al. "Facile Synthesis of Peptidyl Salicylaldehyde Esters and Its Use in Cyclic Peptide Synthesis" Organic Letters 15:5182-5185. (Year: 2013). * |
Also Published As
Publication number | Publication date |
---|---|
KR20180087433A (ko) | 2018-08-01 |
AU2016372510B2 (en) | 2021-07-08 |
EP3390425B1 (en) | 2024-08-07 |
RU2018125630A3 (ja) | 2020-02-26 |
US20220248736A1 (en) | 2022-08-11 |
BR112018012353A2 (pt) | 2018-12-04 |
JP2019505572A (ja) | 2019-02-28 |
EP3390425A1 (en) | 2018-10-24 |
AU2016372510A1 (en) | 2018-06-28 |
CN108473535A (zh) | 2018-08-31 |
MX2018007212A (es) | 2018-11-09 |
RU2018125630A (ru) | 2020-01-20 |
WO2017103200A1 (en) | 2017-06-22 |
US20180368459A1 (en) | 2018-12-27 |
CA3007436A1 (en) | 2017-06-22 |
JP7117779B2 (ja) | 2022-08-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5068174B2 (ja) | Dpp−ivを阻害するペプチド中に濃縮されたタンパク質の加水分解物及びその使用 | |
US20220248736A1 (en) | Dietary peptides | |
Bouglé et al. | Dietary bioactive peptides: Human studies | |
Xu | Bioactive peptides in milk and their biological and health implications | |
Moughan et al. | Food-derived bioactive peptides–a new paradigm | |
US20090270309A1 (en) | Use of lactoferrin fragments and hydrolysates | |
KR20160056941A (ko) | 당뇨병 및 비만의 예방 및 치료를 위한 조성물 및 제형, 그리고 글루코스 및 열량 제어에서 이들의 생성방법 및 용도 | |
RU2388485C2 (ru) | Стимулятор секреции глюкагон-подобного пептида 1, продукты питания или напитки, стимулирующие секрецию глюкагон-подобного пептида 1, ингибитор постпрандиальной гипергликемии и продукты питания или напитки, ингибирующие постпрандиальную гипергликемию | |
TWI353845B (en) | Process for preparing peptide products for promoti | |
Pei et al. | Transport, in vivo antihypertensive effect, and pharmacokinetics of an Angiotensin-Converting Enzyme (ACE) inhibitory peptide LVLPGE | |
Sufian et al. | Soybean β-conglycinin bromelain hydrolysate stimulates cholecystokinin secretion by enteroendocrine STC-1 cells to suppress the appetite of rats under meal-feeding conditions | |
CN106661087A (zh) | 用于改善哺乳动物血糖控制的肽及其组合物 | |
JP2005213260A (ja) | プロテアーゼ阻害剤 | |
US20220315632A1 (en) | Combination of dietary peptides | |
US20230042729A1 (en) | Peptide constructs and compositions | |
EP3916006A1 (en) | Peptides capable of inducing anorexic hormones, compositions and uses thereof | |
Yildiz | 3 Amino Acids, Oligopeptides, Polypeptides, and Proteins | |
JP2022550029A (ja) | 乳清タンパク加水分解物を有効成分として含有する筋減少症の改善、予防又は治療用組成物 | |
AL SHUKOR | MILK AND PEA PROTEIN HYDROLYSATES WITH POTENTIAL TO ACTIVATE CCK1 RECEPTOR | |
TW200914038A (en) | Novel antihypertensive peptide and use thereof | |
TW200902046A (en) | Agents for preventing renal failure |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
AS | Assignment |
Owner name: DIET4LIFE APS, DENMARK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:STAGSTED, JAN;ZHOU, JIEHUI;JESSEN, RANDI;AND OTHERS;SIGNING DATES FROM 20180618 TO 20180620;REEL/FRAME:046218/0123 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE AFTER FINAL ACTION FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: ADVISORY ACTION MAILED |
|
STCT | Information on status: administrative procedure adjustment |
Free format text: PROSECUTION SUSPENDED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |